Skyline Medical to take 20% stake in Helomics, license Illumina ’ s gene sequencing tech

Fresh from its purchase of a 20% stake in joint venture partner Helomics, Skyline Medical (NSDQ:SKLN) said today that it inked a deal to license the MiSeqDx next-generation sequencing technology from Illumina (NSDQ:ILMN). Yesterday Minneapolis-based Skyline said it agreed to buy a lump of convertible shares representing 20% of Helomics, in exchange for 1.1 million newly issued SKLN shares, which combined with its existing right to convert a $500,000 loan would give it a 25% stake in the Pittsburgh-based precision diagnostics and contract research firm. Yesterday’s $1.14 closing price for Skyline stock would value the 20% stake at nearly $1.3 million. “Our strategic growth plan is to invest in, and partner with, leading edge players in emerging areas of the healthcare industry to secure additional income streams and grow the value of Skyline,” CEO Dr. Carl Schwartz said in prepared remarks. “Helomics’ ability to offer data collection, analysis and actionable insights to BioPharma companies as they develop new cancer treatments, positions it as a highly-valuable partner to the fast-growing precision medicine sector. We are pleased to expand our relationship with Helomics through this investment and look forward to helping Helomics’ management to further commercialize its offering.” “Precise analysis of cancer tumors can deliver invaluable insights for cancer diagnostics and aid in the development of target...
Source: Mass Device - Category: Medical Devices Authors: Tags: Diagnostics Genomics Molecular Diagnostics Mergers & Acquisitions Helomics Illumina Inc. Skyline Medical Source Type: news

Related Links:

Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The host immune system plays a pivotal role in the emergence of tumor cells that are refractory to multiple clinical interventions including immunotherapy, chemotherapy, and radiotherapy. Here, we examined the molecular mechanisms by which the immune system triggers cross-resistance to these interventions. By examining the biological changes in murine and tumor cells subjected to sequential rounds of in vitro or in vivo immune selection via cognate cytotoxic T lymphocytes, we found that multimodality resistance arises through a core metabolic reprogramming pathway instigated by epigenetic loss of the ATP synthase subunit A...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
The immunologic landscape of tumors has been continuously unveiled, providing a new look at the interactions between cancer cells and the immune system. Emerging tumor cells are constantly eliminated by the immune system, but some cells establish a long-term equilibrium phase leading to tumor immunoediting and, eventually, evasion. During this process, tumor cells tend to acquire more mutations. Bearing a high mutation burden leads to a greater number of neoantigens with the potential to initiate an immune response. Although many tumors evoke an immune response, tumor clearance by the immune system does not occur due to a ...
Source: Clinics - Category: General Medicine Source Type: research
The objective of this study was to evaluate the frequency of GLS reduction in patients with active cancer and its correlation to other echocardiographic parameters.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Authors: Ding Y, Zhou J, Wang S, Li Y, Mi Y, Gao S, Xu Y, Chen Y, Yan J Abstract Neuropilin-1 (NRP-1) is involved in a range of physiological and pathological processes, including neuronal cell guidance, cardiovascular development, immunity, angiogenesis and the pathogenesis of cancer. Targeting of NRP-1 is considered to be a potential cancer therapy and a number of approaches have been investigated, including the use of small interfering RNA, peptides, soluble NRP antagonists and monoclonal antibodies. The present study used a novel anti-neuropilin-1 monoclonal antibody (anti-NRP-1 mAb) to investigate its potentia...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
We present in vitro evidence that HDACi can enhance the radiosensitivity of human thyroid cancer cells.
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
In this study, we compared the long-term side effects of proton radiation to equivalent doses of X-rays in the initiation and progression of premalignant lesions in a lung cancer susceptible mouse model (K-rasLA1). We show proton irradiation causes more complex DNA damage that is not completely repaired resulting in increased oxidative stress in the lungs both acutely and persistently. We further observed K-rasLA1 mice irradiated with protons had an increased number and size of initiated and premalignant lesions and adenomas that were often infiltrated with inflammatory cells. Proton irradiated mice had a lower median surv...
Source: Life Sciences in Space Research - Category: Biology Source Type: research
This article discusses the pathophysiology and molecular mechanisms that contribute to cancer therapeutics-related cardiac dysfunction and presents an napproach to the evaluation and treatment of these patients.
Source: Heart Failure Clinics - Category: Cardiology Authors: Source Type: research
CONCLUSION: This approach merging qualitative and quantitative data suggests that mMCC patients report a better experience with avelumab than with chemotherapy. PMID: 30107762 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
Local Anesthetics as…Cancer Therapy? Anesth Analg. 2018 Sep;127(3):601-602 Authors: Lynch C PMID: 30113976 [PubMed - in process]
Source: Anesthesia and Analgesia - Category: Anesthesiology Authors: Tags: Anesth Analg Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Contracts | Databases & Libraries | Genetics | Mergers and Aquisitions | Partnerships | Pharmaceuticals